31
Participants
Start Date
July 7, 2022
Primary Completion Date
November 27, 2022
Study Completion Date
November 27, 2022
SYNB1353
SYNB1353 IMP is formulated as a nonsterile solution intended for oral administration. SYNB1353 is subsequently lyophilized to form the bulk drug product. The lyophilized product is sieved into powder form and filled into high-density polyethylene (HDPE) bottles. Placebo will be manufactured using an inactive powder that is color matched to the SYNB1353 drug product. L-Methionine will be supplied as dry powder and will be suspended in a diluent prior to use.
High Point Clinical Trials Center, High Point
Lead Sponsor
Synlogic
INDUSTRY